Skip to main content
    S

    Soligenix Inc. (SNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.33
    -0.02 (-4.81%)

    Market Cap: $7.42M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(24/38)
    Avg Surprise
    -8.42%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.090.0%
    60d ago$-0.090.0%
    30d ago$-0.090.0%
    7d ago$-0.090.0%
    Current$-0.09
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$0.02 - $0.02
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.09---
    Jun 26
    Reported Aug 7
    		$-0.12$-0.22+45.45%Beat+85.4%
    Mar 26
    Reported Apr 3
    		$-0.28$-0.30+6.67%Beat+73.6%
    Dec 25
    Reported Dec 31
    		$N/A$-0.27N/ABeat-
    Sep 25
    Reported Nov 7
    		$-0.58$-0.48-20.83%Miss+25.6%
    Jun 25
    Reported Aug 14
    		$-0.82$-1.05+21.90%Beat+37.4%
    Mar 25
    Reported May 9
    		$-1.06$-0.67-58.21%Miss-488.9%
    Dec 24
    Reported Mar 21
    		$-1.14$-1.56+26.92%Beat+55.5%
    Sep 24
    Reported Nov 8
    		$-0.78N/A+53.85%Beat+69.5%
    Jun 24
    Reported Aug 9
    		$-1.31$-1.77+25.99%Beat+62.8%
    Mar 24
    Reported May 10
    		$-0.18$-0.19+5.26%Beat+96.9%
    Dec 23
    Reported Mar 15
    		$-2.56$-3.12+17.95%Beat+44.1%
    Sep 23
    Reported Nov 13
    		$-2.56$-4.64+44.83%Beat+86.7%
    Jun 23
    Reported Aug 21
    		$-3.52$-6.08+42.11%Beat+74.1%
    Mar 23
    Reported May 15
    		$-5.76N/A+71.20%Beat+76.6%
    Dec 22
    Reported Mar 31
    		$-4.58$-1.12-308.93%Miss-177.6%
    Sep 22
    Reported Nov 10
    		$-19.20$-21.60+11.11%Beat+8.6%
    Jun 22
    Reported Aug 12
    		$-13.58$-24.00+43.42%Beat-13.2%
    Mar 22
    Reported May 13
    		$-24.62$-19.20-28.23%Miss-54.3%
    Dec 21
    Reported Mar 29
    		$-1.65$-1.20-37.50%Miss+31.3%
    Sep 21
    Reported Nov 12
    		$-21.00$-19.20-9.38%Miss-42.8%
    Jun 21
    Reported Aug 13
    		$-12.00N/A+54.55%Beat+52.2%
    Mar 21
    Reported May 17
    		$-15.96$-16.80+5.00%Beat+40.5%
    Dec 20
    Reported Mar 30
    		$-2.40$-1.20-100.00%Miss-14.3%
    Sep 20
    Reported Nov 12
    		$-14.71N/A+56.22%Beat+56.2%
    Jun 20
    Reported Aug 14
    		$-25.08$-38.40+34.69%Beat+12.9%
    Mar 20
    Reported May 15
    		$-26.81$-36.00+25.53%Beat-24.1%
    Dec 19
    Reported Mar 30
    		$-2.10$-1.99-5.53%Miss+22.2%
    Sep 19
    Reported Nov 12
    		$-33.60$-33.60+0.00%Beat-27.3%
    Jun 19
    Reported Aug 13
    		$-28.80$-33.60+14.29%Beat+33.3%
    Mar 19
    Reported May 14
    		$-21.60$40.80-152.94%Miss-7900.0%
    Dec 18
    Reported Mar 26
    		$-2.70$-2.25-20.00%Miss+95.8%
    Sep 18
    Reported Nov 9
    		$-26.40$-24.00-10.00%Miss+35.3%
    Jun 18
    Reported Aug 8
    		$-43.20$-48.00+10.00%Beat+56.1%
    Mar 18
    Reported May 11
    		$-0.27$-0.25-8.00%Miss+94.4%
    Dec 17
    Reported Mar 15
    		$-64.80$-69.60+6.90%Beat+88.5%
    Sep 17
    Reported Nov 6
    		$-40.80N/A+54.05%Beat-
    Jun 17
    Reported Aug 11
    		$-98.40$-77.60-26.80%Miss-
    Mar 17
    Reported May 11
    		$-4.80$-6.75+28.89%Beat-
    Dec 16
    Reported Mar 27
    		$-563.47$-165.60-240.26%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-241.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.77xQuick Ratio2.77x
    Trading Statistics
    Beta2.00Avg Volume229.96K
    52-Week High$1.7652-Week Low$0.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.36
    SMA 20$0.37
    SMA 50$0.38
    SMA 200$0.75
    EMA 10$0.36
    EMA 20$0.36
    EMA 50$0.38
    EMA 200$0.73

    MACD

    Line: -0.01Signal: -0.01Hist: -0.00

    ADX

    ADX: 19.0+DI: 11.4-DI: 24.7

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$0.39

    Bollinger Bands

    Upper Band$0.39
    Lower Band$0.34
    %B Position1509%(Upper)
    Band Width-0.06

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K20.7
    Stoch %D18.5
    Williams %R-94.0
    ROC (10d)-8.3%
    Momentum-0.03
    CCI (20d)-156.8
    MFI (14d)19.8

    Volatility Measures

    ATR (14d)$0.02(4.9%)
    StdDev (20d)0.01
    Hist Vol38.5%(Moderate)

    Volume Flow

    VWAP$0.34
    OBV945.8M
    AD Line-319.0M
    CMF (20d)-0.315

    Volume Metrics

    Avg Vol (20d)233.6K
    Vol Ratio1.1x
    VWMA (20d)$0.37

    Pivot Points

    R3$0.38
    R2$0.38
    R1$0.36
    Pivot Point$0.36
    S1$0.35
    S2$0.34
    S3$0.33

    Advanced Oscillators

    TSI-18.61
    Ultimate Osc22.7
    KST-48.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$6,352$0$2,342$117,029$244,812$130,440
    Cost of Revenue$0$0$1,000$0$0$0$3,175$0$2,342$117,029$221,546$110,441
    Gross Profit$0$0$-1,000$0$0$0$3,176$0$0$0$23,266$19,999
    Operating Expenses$2.10M$2.88M$3.19M$2.58M$2.76M$3.03M$3.71M$1.87M$1.74M$2.12M$2.16M$1.80M
    R&D$974,091$1.78M$2.00M$1.58M$1.68M$1.94M$2.66M$968,689$501,158$1.10M$777,534$826,015
    SG&A$1.13M$1.10M$1.19M$996,604$1.09M$1.08M$1.05M$896,547$1.24M$1.02M$1.38M$973,040
    Operating Income$-2,099,463$-2,884,838$-3,189,111$-2,580,483$-2,763,879$-3,026,508$-3,712,495$-1,865,236$-1,744,675$-2,117,091$-2,137,871$-1,779,056
    Interest Income$53,598$61,389$71,968$52,351$69,823$76,028$70,372$78,836$35,925$28,842$48,270$66,363
    Interest Expense$-58,443$0$0$0$0$0$0$0$0$0$288,630$0
    Income Before Tax$-1,987,354$-2,824,965$-3,117,309$-2,530,947$-2,701,976$-2,951,268$-3,396,480$-1,719,381$-1,644,502$-1,915,327$-2,426,501$-1,662,702
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$-606,606$0
    Net Income$-1,987,354$-2,824,965$-2,610,694$-2,530,947$-2,701,976$-2,951,268$-2,987,366$-1,719,381$-1,644,502$-1,915,327$-1,819,895$-1,662,702
    EBITDA$-2,098,298$-2,885,256$-3,188,275$-2,582,387$-2,771,096$-3,026,688$-3,465,803$-1,796,628$-1,678,839$-1,942,581$-2,473,181$-1,727,476
    EBIT$-2,099,395$-2,886,354$-3,189,277$-2,583,298$-2,771,799$-3,027,296$-3,466,852$-1,798,217$-1,680,427$-1,944,169$-2,474,771$-1,729,065
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNGX

    News

    Form 4 Soligenix Inc: Christopher J. Schaber (Director, CHAIRMAN, CEO AND PRESIDENT) For: 12 October

    This article reports on a Form 4 filing for Soligenix Inc., detailing a transaction by Christopher J. Schaber, who holds roles as Director, Chairman, CEO...

    Investing.com Nigeria•10/14/26•Neutral

    Form 4 Soligenix Inc: Jerome B. Zeldis (Director) For: 12 October

    This article reports a Form 4 filing for Soligenix Inc., indicating that Jerome B. Zeldis, a Director, made a transaction on October 12. The brief notice highlights the company's stock symbol SNGX and its performance. It...

    Investing.com Nigeria•10/14/26•Neutral

    Soligenix Inc (SNGX-Q) Stock Price and News

    This article provides real-time stock price information and news updates for Soligenix Inc (SNGX-Q). It includes a snapshot of its current trading data, key financial metrics, and a compilation of recent news...

    The Globe and Mail•10/13/26•Neutral

    Options for 632 shares are surrendered to Soligenix (SNGX) for cancellation without payment.

    Soligenix, Inc. director Anthony Gregg Lapointe surrendered stock options for 632 shares of Common Stock to the issuer for cancellation on October 12, 2026...

    Stock Titan•10/13/26•Neutral

    For no payment, director Robert J. Rubin surrendered options on 632 Soligenix (SNGX) shares.

    Soligenix, Inc. (SNGX) director Robert J. Rubin voluntarily surrendered stock options for 632 shares of Common Stock to the issuer on October 12, 2026...

    Stock Titan•10/13/26•Neutral

    SNGX Valuation and Fair Value

    Forward P/E
    12.3x
    PEG
    -1.5x
    P/B
    0.8x
    See GNG's fair value

    SNGX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -241.7%

    SNGX Competitors

    CompanyTicker
    Aprea Therapeutics IncAPRE
    XWELL Inc.XWEL
    Senti Biosciences IncSNTI
    InMed Pharmaceuticals IncINM
    Tenon Medical IncTNON
    Predictive Oncology IncPOAI
    Collplant Biotechnologies LtdCLGN
    Skye Bioscience, Inc. Common StockSKYE

    Sector: Healthcare

    SNGX Bull Case vs Bear Case

    Bull case

    • SNGX beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • SNGX's quarterly revenue changed -100.0% year over year.

    SNGX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    12.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About SNGX

    Does SNGX pay dividends?

    Soligenix Inc. (SNGX) does not currently pay a regular dividend.

    What is SNGX's market cap?

    Soligenix Inc. (SNGX) has a market capitalization of $7.42M with a current stock price of $0.33.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In